Literature DB >> 33290280

Loss of Fas signaling in fibroblasts impairs homeostatic fibrosis resolution and promotes persistent pulmonary fibrosis.

Elizabeth F Redente1,2,3, Sangeeta Chakraborty1, Satria Sajuthi4, Bart P Black1, Ben L Edelman1, Max A Seibold1,2,4, David Wh Riches1,2,3,5.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible fibrotic disease of the distal lung alveoli that culminates in respiratory failure and reduced lifespan. Unlike normal lung repair in response to injury, IPF is associated with the accumulation and persistence of fibroblasts and myofibroblasts, as well as continued production of collagen and other extracellular matrix (ECM) components. Prior in vitro studies have led to the hypothesis that the development of resistance to Fas-induced apoptosis by lung fibroblasts and myofibroblasts contributes to their accumulation in the distal lung tissues of IPF patients. Here, we test this hypothesis in vivo in the resolving model of bleomycin-induced pulmonary fibrosis in mice. Using genetic loss-of-function approaches to inhibit Fas signaling in fibroblasts, potentially novel flow cytometry strategies to quantify lung fibroblast subsets, and transcriptional profiling of lung fibroblasts by bulk and single cell RNA sequencing, we show that Fas is necessary for lung fibroblast apoptosis during homeostatic resolution of bleomycin-induced pulmonary fibrosis in vivo. Furthermore, we show that loss of Fas signaling leads to the persistence and continued profibrotic functions of lung fibroblasts. Our studies provide insights into the mechanisms that contribute to fibroblast survival, persistence, and continued ECM deposition in the context of IPF and how failure to undergo Fas-induced apoptosis impairs fibrosis resolution.

Entities:  

Keywords:  Apoptosis; Fas signaling; Fibrosis; Pulmonology

Mesh:

Substances:

Year:  2020        PMID: 33290280      PMCID: PMC7821600          DOI: 10.1172/jci.insight.141618

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  60 in total

Review 1.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease.

Authors:  Thomas A Wynn; Thirumalai R Ramalingam
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

2.  Thy-1 signals through PPARγ to promote lipofibroblast differentiation in the developing lung.

Authors:  Brian M Varisco; Namasivayam Ambalavanan; Jeffrey A Whitsett; James S Hagood
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-20       Impact factor: 6.914

3.  Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis.

Authors:  K Kuwano; N Hagimoto; M Kawasaki; T Yatomi; N Nakamura; S Nagata; T Suda; R Kunitake; T Maeyama; H Miyazaki; N Hara
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

4.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.

Authors:  Maxim V Kuleshov; Matthew R Jones; Andrew D Rouillard; Nicolas F Fernandez; Qiaonan Duan; Zichen Wang; Simon Koplev; Sherry L Jenkins; Kathleen M Jagodnik; Alexander Lachmann; Michael G McDermott; Caroline D Monteiro; Gregory W Gundersen; Avi Ma'ayan
Journal:  Nucleic Acids Res       Date:  2016-05-03       Impact factor: 16.971

Review 5.  Mechanisms of Lung Fibrosis Resolution.

Authors:  Stephan W Glasser; James S Hagood; Simon Wong; Carmen A Taype; Satish K Madala; William D Hardie
Journal:  Am J Pathol       Date:  2016-03-25       Impact factor: 4.307

6.  Resistance to Fas-mediated apoptosis in human lung fibroblast.

Authors:  T Tanaka; M Yoshimi; T Maeyama; N Hagimoto; K Kuwano; N Hara
Journal:  Eur Respir J       Date:  2002-08       Impact factor: 16.671

7.  Differential expression of interleukin 1 alpha by Thy-1+ and Thy-1- lung fibroblast subpopulations: enhancement of interleukin 1 alpha production by tumor necrosis factor-alpha.

Authors:  R P Phipps; C Baecher; J G Frelinger; D P Penney; P Keng; D Brown
Journal:  Eur J Immunol       Date:  1990-08       Impact factor: 5.532

8.  Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis.

Authors:  Tatiana Kisseleva; Min Cong; Yonghan Paik; David Scholten; Chunyan Jiang; Chris Benner; Keiko Iwaisako; Thomas Moore-Morris; Brian Scott; Hidekazu Tsukamoto; Sylvia M Evans; Wolfgang Dillmann; Christopher K Glass; David A Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-07       Impact factor: 11.205

9.  Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis.

Authors:  Regina Golan-Gerstl; Shulamit B Wallach-Dayan; Philip Zisman; Wellington V Cardoso; Ronald H Goldstein; Raphael Breuer
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-10       Impact factor: 6.914

10.  Specification and Diversification of Pericytes and Smooth Muscle Cells from Mesenchymoangioblasts.

Authors:  Akhilesh Kumar; Saritha Sandra D'Souza; Oleg V Moskvin; Huishi Toh; Bowen Wang; Jue Zhang; Scott Swanson; Lian-Wang Guo; James A Thomson; Igor I Slukvin
Journal:  Cell Rep       Date:  2017-05-30       Impact factor: 9.423

View more
  9 in total

Review 1.  Evaluation of Proteasome Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis.

Authors:  I-Chen Chen; Yi-Ching Liu; Yen-Hsien Wu; Shih-Hsing Lo; Zen-Kong Dai; Jong-Hau Hsu; Yu-Hsin Tseng
Journal:  Cells       Date:  2022-05-04       Impact factor: 7.666

Review 2.  Identification, discrimination and heterogeneity of fibroblasts.

Authors:  Urban Lendahl; Lars Muhl; Christer Betsholtz
Journal:  Nat Commun       Date:  2022-06-14       Impact factor: 17.694

3.  Transcriptional analysis of lung fibroblasts identifies PIM1 signaling as a driver of aging-associated persistent fibrosis.

Authors:  Tho X Pham; Jisu Lee; Jiazhen Guan; Nunzia Caporarello; Jeffrey A Meridew; Dakota L Jones; Qi Tan; Steven K Huang; Daniel J Tschumperlin; Giovanni Ligresti
Journal:  JCI Insight       Date:  2022-03-22

4.  Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis.

Authors:  Abhalaxmi Singh; Sreeparna Chakraborty; Sing Wan Wong; Nicole A Hefner; Andrew Stuart; Abdul S Qadir; Amitabha Mukhopadhyay; Kurt Bachmaier; Jae-Won Shin; Jalees Rehman; Asrar B Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-04       Impact factor: 12.779

5.  KLF4 is a therapeutically tractable brake on fibroblast activation that promotes resolution of pulmonary fibrosis.

Authors:  Loka R Penke; Jennifer M Speth; Steven K Huang; Sean M Fortier; Jared Baas; Marc Peters-Golden
Journal:  JCI Insight       Date:  2022-08-22

Review 6.  The Epithelial-Immune Crosstalk in Pulmonary Fibrosis.

Authors:  Thomas Planté-Bordeneuve; Charles Pilette; Antoine Froidure
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

7.  CD105+CD90+CD13+ identifies a clonogenic subset of adventitial lung fibroblasts.

Authors:  Måns Kadefors; Sara Rolandsson Enes; Emma Åhrman; Barbora Michaliková; Anna Löfdahl; Göran Dellgren; Stefan Scheding; Gunilla Westergren-Thorsson
Journal:  Sci Rep       Date:  2021-12-24       Impact factor: 4.379

Review 8.  Irreversibility of Pulmonary Fibrosis.

Authors:  Qing Yang Yu; Xiao Xiao Tang
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 6.745

9.  Dysregulated overexpression of Sox9 induces fibroblast activation in pulmonary fibrosis.

Authors:  Prathibha R Gajjala; Rajesh K Kasam; Divyalakshmi Soundararajan; Debora Sinner; Steven K Huang; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2021-10-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.